Impairment of drug metabolism in polycystic non-parasitic liver disease.

1. Drug-metabolizing capacity in cases of polycystic non-parasitic liver disease was investigated using plasma antipyrine clearance as an index. 2. The four subjects with maternally inherited polycystic liver metabolized antipyrine at a significantly slower rate than the six other members of the family. 3. This reduction in antipyrine metabolism is due to the loss of active liver parenchyma, and is probably also influenced by alterations in the vascular bed due to compression by the enlarged cysts.
AuthorsE A Sotaniemi, P V Luoma, P M Järvensivu, K A Sotaniemi
JournalBritish journal of clinical pharmacology (Br J Clin Pharmacol) Vol. 8 Issue 4 Pg. 331-5 (Oct 1979) ISSN: 0306-5251 [Print] ENGLAND
PMID508507 (Publication Type: Journal Article)
Chemical References
  • Pharmaceutical Preparations
  • Antipyrine
  • Adult
  • Antipyrine (metabolism)
  • Cysts (genetics, metabolism, radionuclide imaging)
  • Female
  • Half-Life
  • Humans
  • Liver Diseases (genetics, metabolism, radionuclide imaging)
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Pharmaceutical Preparations (metabolism)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: